Evidence for Effective Multiple K+-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V2 Receptor

Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan

(2018) Jesse H. Morris et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Multiple regulatory actions of 2-guanidine-4-methylquinazoline (GMQ), an agonist of acid-sensing ion channel type 3, on ionic currents in pituitary GH 3 cells and in olfactory sensory (Rolf B1.T) neurons

(2018) Edmund Cheung So et al.   BIOCHEMICAL PHARMACOLOGY

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

(2018) Marie E. Edwards et al.   Clinical Journal of the American Society of Nephrology

Tolvaptan for Heart Failure in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis

(2018) Jonathan Sen et al.   Heart Lung and Circulation

Comparison of two dosing methods for immediate administration of tolvaptan in acute decompensated heart failure

(2018) Mitsutoshi Oguri et al.   Journal of Cardiology

A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model

(2018) Phil McEwan et al.   BMC Nephrology

Vasopressin antagonism for decompensated right-sided heart failure

(2018) Andrija Vidic et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan

(2018) Fouad T. Chebib et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Pioglitazone, a PPAR-γ Activator, Stimulates BKCa but Suppresses IKM in Hippocampal Neurons

(2018) Tsang-Shan Chen et al.   Frontiers in Pharmacology

Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry

(2018) Samuel H. Sigal et al.   Canadian Journal of Gastroenterology and Hepatology

Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease

(2018) Masahiko Oguro et al.   JOURNAL OF NEPHROLOGY

A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan

(2018) Hideyuki Takimura et al.   PLoS One

Update of acute and long-term tolvaptan therapy

(2018) Teruhiko Imamura et al.   Journal of Cardiology

Good response to tolvaptan shortens hospitalization in patients with congestive heart failure

(2017) Tomohito Kogure et al.   HEART AND VESSELS

Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure

(2017) Ryuichi Matsukawa et al.   HEART AND VESSELS

The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment

(2017) Grazia Tamma et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Stimulatory actions of a novel thiourea derivative on large-conductance, calcium-activated potassium channels

(2017) Sheng-Nan Wu et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The vasopressin system: new insights for patients with kidney diseases

(2017) W. F. Clark et al.   JOURNAL OF INTERNAL MEDICINE

Tolvaptan-Type Vasopressin Receptor Ligands: Important Role of Axial Chirality in the Active Form

(2017) Hidetsugu Tabata et al.   JOURNAL OF MEDICINAL CHEMISTRY

Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure

(2017) G. Michael Felker et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload

(2017) Marvin A. Konstam et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

(2017) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients

(2017) Caroline Der-Nigoghossian et al.   PHARMACOTHERAPY

Current Management of Hyponatremia in Acute Heart Failure: A Report From the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry)

(2017) Mark E. Dunlap et al.   Journal of the American Heart Association

Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials

(2017) Richard J. Gralla et al.   Cancer Medicine

Emerging Therapies for Childhood Polycystic Kidney Disease

(2017) William E. Sweeney et al.   Frontiers in Pediatrics

Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis

(2017) Mei-Yi Wu et al.   PLoS One

Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca2+ entry pathway

(2017) Saifur Rahman et al.   Scientific Reports

Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT)

(2016) Joseph G. Verbalis et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

HCN Channels Modulators: The Need for Selectivity

(2016) Maria Novella Romanelli et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease

(2016) Romina Mancinelli et al.   LABORATORY INVESTIGATION

Association between plasma concentration of tolvaptan and urine volume in acute decompensated heart failure patients with fluid overload

(2016) Mahoto Kato et al.   Cardiology Journal

‘Dos and don’ts’ in the management of hyponatremia

(2015) Simon Aylwin et al.   CURRENT MEDICAL RESEARCH AND OPINION

Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis

(2015) Vishwadeep Ahluwalia et al.   JOURNAL OF HEPATOLOGY

Ability of naringenin, a bioflavonoid, to activate M-type potassium current in motor neuron-like cells and to increase BKCa-channel activity in HEK293T cells transfected with α-hSlo subunit

(2014) Hung-Te Hsu et al.   BMC NEUROSCIENCE

Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1Breceptor antagonists: TASP0233278 and TASP0390325

(2014) M Iijima et al.   BRITISH JOURNAL OF PHARMACOLOGY

Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure

(2014) Yasukatsu Izumi et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Characterization of Three Vasopressin Receptor 2 Variants: An Apparent Polymorphism (V266A) and Two Loss-of-Function Mutations (R181C and M311V)

(2013) Stephen P. Armstrong et al.   PLoS One

Trafficking of the IKs-Complex in MDCK Cells: Site of Subunit Assembly and Determinants of Polarized Localization

(2013) Jens-Peter David et al.   TRAFFIC

Electrophysiological characterization of sodium-activated potassium channels in NG108-15 and NSC-34 motor neuron-like cells

(2012) S.-N. Wu et al.   Acta Physiologica

The inhibition by di(2-ethylhexyl)-phthalate of erg-mediated K+ current in pituitary tumor (GH3) cells

(2012) Sheng-Nan Wu et al.   ARCHIVES OF TOXICOLOGY

Evidence for Inhibitory Effects of Flupirtine, a Centrally Acting Analgesic, on Delayed Rectifier K+Currents in Motor Neuron-Like Cells

(2012) Sheng-Nan Wu et al.   Evidence-based Complementary and Alternative Medicine

Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug

(2012) Giorgio Graziani et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Tolvaptan

(2009) Jalal K. Ghali et al.   NATURE REVIEWS DRUG DISCOVERY

Tramadol-induced block of hyperpolarization-activated cation current in rat pituitary lactotrophs

(2008) Yen-Chin Liu et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY